Biodesix (BDSX) News Today → **Breaking News** LIttle Known Biotech Company Does $41 Million In Q1! (From Huge Alerts) (Ad) Free BDSX Stock Alerts $1.57 0.00 (0.00%) (As of 05/20/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 16, 2024 | marketbeat.comBiodesix, Inc. (NASDAQ:BDSX) Short Interest Up 9.7% in AprilBiodesix, Inc. (NASDAQ:BDSX - Get Free Report) saw a large growth in short interest during the month of April. As of April 30th, there was short interest totalling 345,600 shares, a growth of 9.7% from the April 15th total of 315,000 shares. Based on an average daily volume of 140,300 shares, the short-interest ratio is presently 2.5 days.May 15, 2024 | americanbankingnews.comTD Cowen Begins Coverage on Biodesix (NASDAQ:BDSX)May 13, 2024 | markets.businessinsider.comBuy Rating Justified by Biodesix’s Market Leadership and Strong Growth ProspectsMay 13, 2024 | marketbeat.comBiodesix (NASDAQ:BDSX) Now Covered by Analysts at TD CowenTD Cowen began coverage on Biodesix in a research report on Monday. They set a "buy" rating and a $2.80 price objective on the stock.May 11, 2024 | finance.yahoo.comBiodesix, Inc. (NASDAQ:BDSX) Just Reported Earnings, And Analysts Cut Their Target PriceMay 10, 2024 | finance.yahoo.comBiodesix Inc (BDSX) Surpasses Analyst Revenue Forecasts with Strong Q1 2024 PerformanceMay 10, 2024 | finance.yahoo.comBiodesix, Inc. (NASDAQ:BDSX) Q1 2024 Earnings Call TranscriptMay 10, 2024 | finance.yahoo.comBiodesix First Quarter 2024 Earnings: Beats ExpectationsMay 9, 2024 | finance.yahoo.comBiodesix Inc (BDSX) Q1 2024 Earnings Call Transcript Highlights: Strong Revenue Growth and ...May 8, 2024 | investorplace.comBDSX Stock Earnings: Biodesix Beats EPS, Beats Revenue for Q1 2024May 8, 2024 | finance.yahoo.comBiodesix Announces First Quarter 2024 Results Driven by Growth in Lung Diagnostic Testing for Lung Nodule ManagementMay 7, 2024 | businesswire.comBiodesix to Participate in the 2024 RBCCM Global Healthcare ConferenceMay 3, 2024 | marketbeat.comBiodesix (NASDAQ:BDSX) Earns Buy Rating from Analysts at Lake Street CapitalLake Street Capital assumed coverage on Biodesix in a research note on Friday. They issued a "buy" rating and a $3.00 price target for the company.May 1, 2024 | marketbeat.comBiodesix (BDSX) Scheduled to Post Earnings on WednesdayBiodesix (NASDAQ:BDSX) will be releasing earnings after the market closes on Wednesday, May 8, Zacks reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=588280)April 29, 2024 | marketbeat.comBiodesix, Inc. (NASDAQ:BDSX) Short Interest Up 13.6% in AprilBiodesix, Inc. (NASDAQ:BDSX - Get Free Report) saw a significant growth in short interest during the month of April. As of April 15th, there was short interest totalling 315,000 shares, a growth of 13.6% from the March 31st total of 277,400 shares. Based on an average trading volume of 158,200 shares, the days-to-cover ratio is currently 2.0 days.April 24, 2024 | businesswire.comBiodesix to Report First Quarter 2024 Financial Results on May 8, 2024April 13, 2024 | finance.yahoo.comThe recent US$4.0m market cap decrease is likely to have disappointed insiders invested in Biodesix, Inc. (NASDAQ:BDSX)April 12, 2024 | marketbeat.comBiodesix, Inc. (NASDAQ:BDSX) Sees Large Increase in Short InterestBiodesix, Inc. (NASDAQ:BDSX - Get Free Report) was the target of a significant increase in short interest during the month of March. As of March 31st, there was short interest totalling 277,400 shares, an increase of 53.2% from the March 15th total of 181,100 shares. Based on an average trading volume of 163,400 shares, the days-to-cover ratio is currently 1.7 days. Approximately 1.1% of the company's stock are sold short.April 9, 2024 | businesswire.comBiodesix to Present New Data on Liquid Biopsy Technologies at AACR 2024 Annual MeetingApril 5, 2024 | markets.businessinsider.comS&P 500 Gains Over 1%; GCT Semiconductor Shares Spike HigherApril 5, 2024 | markets.businessinsider.comGold Surges Over 1%; Biodesix Shares PlummetApril 5, 2024 | businesswire.comBiodesix Announces Pricing of Oversubscribed and Upsized Underwritten Offering of Common Stock and Concurrent Private PlacementMarch 25, 2024 | businesswire.comBiodesix Announces New Master Collaborative Research Agreement with Leading US Cancer CenterMarch 18, 2024 | marketbeat.comBiodesix, Inc. (NASDAQ:BDSX) Short Interest UpdateBiodesix, Inc. (NASDAQ:BDSX - Get Free Report) was the target of a large decline in short interest in February. As of February 29th, there was short interest totalling 161,500 shares, a decline of 5.1% from the February 14th total of 170,100 shares. Based on an average daily trading volume, of 132,800 shares, the short-interest ratio is presently 1.2 days. Approximately 0.7% of the shares of the stock are short sold.March 4, 2024 | finance.yahoo.comBiodesix, Inc. (NASDAQ:BDSX) Q4 2023 Earnings Call TranscriptMarch 3, 2024 | finance.yahoo.comBiodesix Full Year 2023 Earnings: EPS Beats Expectations, Revenues LagMarch 3, 2024 | marketbeat.comBiodesix, Inc. (NASDAQ:BDSX) Short Interest Down 13.5% in FebruaryBiodesix, Inc. (NASDAQ:BDSX - Get Free Report) was the recipient of a significant decline in short interest in February. As of February 15th, there was short interest totalling 170,100 shares, a decline of 13.5% from the January 31st total of 196,700 shares. Currently, 0.7% of the shares of the stock are sold short. Based on an average daily volume of 119,300 shares, the days-to-cover ratio is currently 1.4 days.March 1, 2024 | finance.yahoo.comBiodesix Inc (BDSX) Reports Strong Growth in Lung Diagnostic Test Volume and Gross Profit MarginMarch 1, 2024 | businesswire.comBiodesix Announces Fourth Quarter and Fiscal Year 2023 Results and Business HighlightsFebruary 26, 2024 | businesswire.comBiodesix to Participate in the TD Cowen 44th Annual Health Care ConferenceFebruary 16, 2024 | finance.yahoo.comBiodesix to Report Fourth Quarter and Full Year 2023 Financial Results on March 1, 2024February 16, 2024 | businesswire.comBiodesix to Report Fourth Quarter and Full Year 2023 Financial Results on March 1, 2024February 13, 2024 | finance.yahoo.comBiodesix Inc CEO Scott Hutton Sells 64,390 SharesFebruary 2, 2024 | finance.yahoo.comOne Biodesix Insider Raised Their Stake In The Previous YearNovember 14, 2023 | finance.yahoo.comBiodesix Enhances Access to Nodify Lung® Testing with Launch of New Blood Draw MethodNovember 9, 2023 | finance.yahoo.comBiodesix to Participate in Two Upcoming Investor Conferences in NovemberNovember 7, 2023 | finance.yahoo.comBiodesix Announces Third Quarter 2023 Results and HighlightsNovember 6, 2023 | markets.businessinsider.comHere's what Wall Street expects from Biodesix's earningsOctober 24, 2023 | finance.yahoo.comBiodesix to Report Third Quarter 2023 Financial Results on November 7, 2023October 3, 2023 | finance.yahoo.comBiodesix to Present New Data on Nodify Lung® Testing at CHEST 2023 Annual MeetingSeptember 15, 2023 | marketbeat.comLegato Capital Management LLC Grows Holdings in Biodesix, Inc. (NASDAQ:BDSX)Legato Capital Management LLC grew its holdings in shares of Biodesix, Inc. (NASDAQ:BDSX - Free Report) by 541.7% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 205,052 shares of the company's stock after buyingSeptember 7, 2023 | finance.yahoo.comBiodesix Announces Two Presentations on Lung Cancer Treatment Guidance Tests at the IASLC 2023 World Lung Conference on Lung CancerAugust 26, 2023 | finance.yahoo.comJack Schuler Spends US$217k On Biodesix StockAugust 22, 2023 | finance.yahoo.comBiodesix Announces Presentation of New Nodify XL2® Data at AABIP Conference Highlighting Increased Proportion of Biopsies Diagnosing CancerAugust 18, 2023 | marketbeat.comBiodesix, Inc. (NASDAQ:BDSX) Forecasted to Earn FY2023 Earnings of ($0.68) Per ShareBiodesix, Inc. (NASDAQ:BDSX - Free Report) - Investment analysts at William Blair increased their FY2023 earnings per share (EPS) estimates for Biodesix in a research report issued to clients and investors on Tuesday, August 15th. William Blair analyst A. Brackmann now anticipates that the companAugust 9, 2023 | finance.yahoo.comBiodesix, Inc. (NASDAQ:BDSX) Q2 2023 Earnings Call TranscriptAugust 1, 2023 | finance.yahoo.comBiodesix to Participate in the Canaccord Genuity 43rd Annual Growth ConferenceJuly 26, 2023 | finance.yahoo.comBiodesix (NASDAQ:BDSX) investors are sitting on a loss of 49% if they invested a year agoJuly 24, 2023 | finance.yahoo.comBiodesix to Report Second Quarter 2023 Financial Results on August 7, 2023July 12, 2023 | finance.yahoo.comBiodesix Announces Publication of the ORACLE Clinical Utility Study with the Primary Endpoint Demonstrating that the Nodify XL2® Test Reduced Unnecessary Invasive Procedures on Benign Lung Nodules Get Biodesix News Delivered to You Automatically Sign up to receive the latest news and ratings for BDSX and its competitors with MarketBeat's FREE daily newsletter. Email Address [FREE Ticket] 27 Crypto Experts Reveal Their #1 Picks (Ad)Are you monitoring 13,217 cryptocurrencies everyday? If not, you could miss the ONE that can make you wealthy beyond your wildest dreams. You see, while Bitcoin and Ethereum steal all the headlines… It’s often the cryptos flying under the radar that turn small stakes into life-changing windfalls. Claim your free seat by clicking here now. BDSX Media Mentions By Week BDSX Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. BDSX News Sentiment▼0.920.42▲Average Medical News Sentiment BDSX News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. BDSX Articles This Week▼21▲BDSX Articles Average Week Get Biodesix News Delivered to You Automatically Sign up to receive the latest news and ratings for BDSX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: PSNL News Today SERA News Today ENZ News Today RNLX News Today XGN News Today DMTK News Today CNTG News Today CELC News Today CSTL News Today FLGT News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:BDSX) was last updated on 5/20/2024 by MarketBeat.com Staff From Our PartnersThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsShocking $16T Elon Musk Crypto LeakCrypto 101 MediaDid You Get Your Free Bitcoin Yet?Crypto Swap Profits4 Cryptos BETTER than BitcoinTrue Market InsidersNext President (Not Trump. Not Biden.)The Freeport SocietyThe #1 Crypto for AIWeiss Ratings**Breaking News** LIttle Known Biotech Company Does $41 Million In Q1! Huge Alerts Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biodesix, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
